Stem Cell Transplant Reviewed for Peripheral T-Cell Lymphoma
Three- and five-year overall survival similar with allogeneic or autologous HSCT, but transplant-related mortality higher with allogeneic HSCT
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.